Jim Cramer made the following calls on September 27th, 2013. What do you think about his picks?
Dunkin’ Brands Group Inc. (NASDAQ:DNKN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 26, 2013. The stock’s 52-week high is $46.50, and its 52-week low is $28.62. Cramer was optimistic about Dunkin Brands, using it to explain the meaning of his “regional to national” growth expression. The phrase means that Dunkin is focused primarily in the northeast, giving it lots of room to expand throughout the country. In effect, there are hundreds, if not thousands, of stores that Dunkin could open in the United States alone. This leaves lots of room for the stock to grow as the company expands.
GameStop Corp. (NYSE:GME): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 16, 2013. The stock’s 52-week high is $56.08, and its 52-week low is $21.05. Cramer claimed that GameStop could pose an opportunity to investors who are looking to buy on weakness, as any downward fluctuation at the moment would present a prime scenario. With the holiday season ahead, and big video game titles and consoles yets to be released, Cramer believes that now is a good time to jump on board with the company.
Array BioPharma, Inc. (NASDAQ:ARRY): Jim Cramer ranked this stock a Buy. The stock’s 52-week high is $7.10, and its 52-week low is $3.25. Cramer highlighted Array as an example of a great biotech stock, pointing to its strong scientific performance, good business decision making, and an ability to form many partnerships to bolster the company’s name and value. Cramer also said that its drug named 502 could be one of the first advances in the field of asthma medication to come out in the last 15 years.
Cyan Inc. (NYSE:CYNI): Jim Cramer ranked this stock a Sell. The stock’s 52-week high is $15.05, and its 52-week low is $7.85. Cramer was not optimistic about Cyan, a company that debuted earlier this year. He said that the company missed its targets during the first quarter in which it was publicly traded, making it not a good call compared to other fledgling companies that one could invest in.
Don’t Miss: Analyst: Apple May Start 2014 With a Flop.